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 So, rather than normally being purged 
of anti-self antibodies and lymphocytes by 
 horror autotoxicus and elimination of for-
bidden clones, all of us are bathed in ben-
eficial autoantibodies that react with 
ourselves. If so, pathogenic autoimmunity 
can be envisioned more as a dysregulation 
of natural homeo static autoimmunity 
rather than the onset of a previously absent 
state of self-recognition. 
 DISCLOSURE 
 The authors declared no competing interests. 
 REFERENCES 
 1 .  Cui  Z ,  Zhao  M-h ,  Segelmark  M  et al.  Natural 
autoantibodies to myeloperoxidase, proteinase 3, 
and the glomerular basement membrane are present 
in normal individuals .  Kidney Int  2010 ;  78 :  590 – 597 . 
 2 .  Ehrlich  P .  On immunity with special reference to 
cell life .  Proc R Soc Lond  1900 ;  66 :  424 – 448 . 
 3 .  Tauber  AI .  Metchnikoff and the phagocytosis 
theory .  Nat Rev Mol Cell Biol  2003 ;  4 :  897 – 901 . 
 4 .  Besredka  A .  Les antihemolysines naturelles .  Ann 
Inst Pasteur (Paris)  1901 ;  15 :  785 – 807 . 
 5 .  Burnet  FM .  The Clonal Selection Theory of Acquired 
Immunity .  Vanderbilt University Press: Nashville , 
 1959 ,  p  122 . 
 6 .  Donath  J ,  Landsteiner  K .  Uber paroxysmale 
haemoglobinurie .  Munch Med Wochenschr  1904 ; 
 51 :  1590 – 1593 . 
 7 .  Cohn  M ,  Mitchison  NA ,  Paul  WE  et al.  Reflections 
on the clonal-selection theory .  Nat Rev Immunol 
 2007 ;  7 :  823 – 830 . 
 8 .  Jerne  NK .  Towards a network theory of the 
immune system .  Ann Immunol (Paris)  1974 ;  125C : 
 373 – 389 . 
 9 .  Cohn  M .  The concept of functional idiotype network 
for immune regulation mocks all and comforts none . 
 Ann Inst Pasteur Immunol  1986 ;  137C :  64 – 76 . 
 10 .  Avrameas  S ,  Ternynck  T ,  Tsonis  IA  et al.  Naturally 
occurring B-cell autoreactivity: a critical overview . 
 J Autoimmun  2007 ;  29 :  213 – 218 . 
 11 .  Elkon  K ,  Casali  P .  Nature and function of auto anti-
bodies .  Nat Clin Pract Rheumatol  2008 ;  4 :  491 – 498 . 
see original article on page 578
 Lead-time bias in studies of 
cinacalcet prescriptions 
 Marie  Evans 1 and  Carl Michael  Fored 2 
 Observational studies have suggested a link between higher serum 
phosphate, calcium, parathyroid hormone levels, and cardiovascular 
mortality. The administration of cinacalcet has proven efficient in the 
treatment of secondary hyperparathyroidism among hemodialysis 
patients. In an observational study by Block  et al. , cinacalcet treatment 
is associated with a much improved all-cause and cardiovascular 
mortality. However, the results should be interpreted cautiously, as 
observational studies may be influenced by bias. This Commentary 
discusses the role of some common potential biases. 
 Kidney International (2010)  78, 535 – 537.  doi: 10.1038/ki.2010.220 
 Nephrologists try hard to unveil the etio-
logy behind the increased cardiovascular 
mortality among hemodialysis patients. 
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Observational studies have been able to 
show that a high plasma phosphorus and 
calcium are independent risk factors for 
cardiovascular events, and all-cause mor-
tality. 1 Th e relationship of parathyroid hor-
mone (PTH) is more complex; both high 
and low values are associated with 
increased mortality. Control of calcium, 
phosphate, and PTH has proven essential; 
the length of time for which a dialysis 
patient achieves the targets, and simultane-
ous control of all three of them, are associ-
ated with improved survival. 2 Because 
these three laboratory values are closely 
interconnected, we look with enthusiasm 
at cinacalcet, which has the potential to 
improve all of them. In addition to excel-
lent results on laboratory parameters, cina-
calcet has also shown favorable eff ects on 
cardiovascular hospitalization, fractures, 
parathyroidectomy, and quality of life. 3 
However, data on hard clinical outcomes, 
such as mortality, have been scarce. Dur-
ing the past decade, a number of negative 
randomized controlled trials have 
emerged among hemodialysis patients. 
These trials have showed that neither 
increasing the dose of hemodialysis or 
peritoneal dialysis, nor treating patients 
with statins, B vitamins, or erythropoietin, 
had any eff ect on the survival in this high-
risk population. 4 In the light of all the nega-
tive trials, the study by Block  et al. 5 (this 
issue) brings new hope to the renal com-
munity, as it shows a 27 % improvement in 
all-cause mortality among cinacalcet-treated 
compared with non-treated patients. 
 Th ere is reason, however, to regard the 
fi ndings of this observational study with 
some caution. Indeed, some of the above-
mentioned negative randomized trials were 
preceded by observational studies that 
showed favorable eff ects of intervention. A 
frequent problem in observational studies 
is bias due to  ‘ confounding by indication. ’ 6 
Th is means that the very reason for an indi-
vidual to receive a treatment or not receive 
a treatment is associated with factors (oft en 
disease status) that in turn are related to the 
outcome — in this example, mortality. Epi-
demiologists try to deal with confounding 
by indication by adjustments for as many 
risk factors as possible that are related to 
the diff erences in treatment assignment. 
Th e problem is that we can only adjust for 
measured covariates. Sometimes diff er-
ences between patients are subtle, and more 
diffi  cult to describe than a simple statement 
of comorbid conditions can do. How can 
we describe the  ‘ clinician ’ s eye ’ for the 
patient ’ s general condition? Th us, unmeas-
ured covariates and insuffi  cient resolution 
among the measured ones may give rise to 
residual confounding by indication. In the 
paper by Block  et al. , 5 the results were 
adjusted for the fact that the patients receiv-
ing cinacalcet were younger and had 
lower prevalence of diabetes, fewer hospital 
days, and higher body mass index 
and serum albumin levels. In addition, the 
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non-treatment group had higher frequency 
of comorbidities in all of the investigated 
conditions. However, in spite of higher 
prevalence of atherosclerotic heart disease, 
congestive heart failure, and peripheral 
vascular disease, the number of prescrip-
tions of beta-blockers, calcium channel 
blockers, and angiotensin-converting 
enzyme inhibitors was lower among non-
treated patients. On the basis of the infor-
mation in the study, we do not know 
whether the reason was a lower blood pres-
sure, more side eff ects, or just a lower-inter-
vention policy among non-treated patients. 
Th e treated patients also had a longer dial-
ysis vintage at fi rst inclusion, something 
that is not easily understood but may be 
related to their being a selected group of 
 ‘ survivors. ’ The preferential selection of 
healthier patients into the treatment group 
is a problem also in advanced statistical 
time-dependent models. Like treatment 
with cinacalcet, treatment with vitamin D 
is also linked to better health status and 
improved survival in observational studies 
of hemodialysis patients. Yet recently the 
survival advantage was questioned in a large 
observational study in which there was no 
treatment eff ect when models to take care 
of unmeasured confounding were used. 7 
 When it comes to secondary hyperpara-
thyroidism, there were, as expected, already 
diff erences in laboratory measurements 
between treated and non-treated patients 
at the time of inclusion. Th ese baseline dif-
ferences in PTH, phosphorus, and calcium 
were properly adjusted for, but we do not 
know whether these measures adjust com-
pletely for diff erences that adhere to stage 
of disease. Th e perturbed bone and min-
eral metabolism, starting already in early 
stages of chronic kidney disease, is believed 
to cause vascular calcifi cation that itself is 
closely associated with cardiovascular 
mortality. Among patients with early 
chronic kidney disease, higher phosphate 
is associated with an increased vascular 
calcifi cation score, 8 but among prevalent 
dialysis patients, the only independent fac-
tors associated with calcifi cation score are 
age, dialysis vintage, and factors linked to 
comorbidity. 9,10 If PTH, calcium, and 
phosphate among dialysis patients are not 
enough to predict calcifi cation score and 
baseline disease status, the treatment 
group may still have been earlier in their 
course of disease with less vascular calcifi -
cation in spite of the higher PTH values at 
inclusion, and that would have caused a 
lead-time bias problem ( Figure 1 ). It is of 
course only hypothetical and maybe not 
reasonable that patients with a lower cal-
cifi cation score would have a greater chance 
of receiving cinacalcet, but the reason 
patients were assigned or not assigned a 
treatment is not clear. As an example, 15 % 
of the patients in this study received cina-
calcet when their PTH levels were still 
within the recommended guidelines (  300 
pg / ml), while 43 % of the patients with PTH 
values greater than 600 pg / ml at baseline 
belonged to the non-treatment group. 
 The time-dependent analysis design 
used in the study is a way of adjusting for 
the problem that the longer a patient is 
alive, the greater is his or her probability of 
receiving the treatment. Th is is sometimes 
referred to as survivor treatment selection 
bias. 11 Time-dependent models are pre-
ferred in analyses such as this because they 
compare mortality among treated and 
non-treated patients at one time point with 
mortality among other patients who have 
survived that far. However, bias may still 
remain if there is a time-dependent con-
founder that is aff ected by earlier treatment 
levels. 12 Examples of potential time-
dependent confounders in the study by 
Block  et al. 5 are PTH, calcium, and phos-
phate levels. Even though it may be correct 
not to adjust for them during follow-up 
(because they were mediators of the eff ect 
of cinacalcet), the decision is not trivial; 
they are also confounders because they are 
independently associated with mortality 
and predict the chance of getting the treat-
ment. To allow full adjustment for time-
dependent confounders in observational 
studies, there is a need for even more 
advanced statistical methods, such as mar-
ginal structural models. 
 In our ambition to improve outcome in 
dialysis patients, it is easy to be dazzled by 
the message of this well-conducted obser-
vational study indicating a 27 % better 
survival with cinacalcet treatment. No 
other treatment known to us seems 
equally benefi cial. Before this attractive 
treatment option is introduced more 
widely in clinical practice, it is, however, 
important to remember the potential pit-
falls with observational studies. Th us, we 
have every reason to wait for the results of 
the upcoming EVOLVE trial before 
we adopt new and expensive treatment 
strategies in hemodialysis patients with 
secondary hyperparathyroidism. 
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 Figure 1  |  An example of lead-time bias. If a patient  A is included earlier in the course of disease, 
the survival time will be longer, even if we adjust for the differences in survival that adhere to age, 
compared with a patient  B included at a later stage. SHPT, secondary hyperparathyroidism.  
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 CD14 : a candidate biomarker 
for the prognosis of 
polycystic kidney disease 
 Gregory B.  Vanden Heuvel 1 
 Zhou  et al. validate the expression of markers of the innate immune 
system in the cpk mouse model of polycystic kidney disease (PKD), in 
human recessive PKD, and in human autosomal dominant PKD and show 
that CD14 expression correlates with PKD progression, even from very 
early stages of disease. Moreover, they show that CD14 is expressed from the 
renal tubule epithelial cells, suggesting a mechanism of Toll-like 
receptor-4 activation in PKD prior to the infiltration of inflammatory cells. 
 Kidney International (2010)  78, 537 – 538.  doi: 10.1038/ki.2010.228 
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 Polycystic kidney disease (PKD) is char-
acterized by a disruption in tubular epi-
thelial cells that leads to inappropriate cell 
proliferation, increased fl uid secretion, 
abnormal differentiation, and altered 
extracellular matrix that all contribute to 
the development of numerous renal cysts 
in the kidney. Countless studies have 
focused on the role of cell proliferation, 
fl uid secretion, apoptosis, and extracel-
lular matrix in the progression and patho-
genesis of this devastating disease. 1 Th ese 
studies have led to a better understanding 
of the progression of the disease, and, 
in some cases, to potential therapeutic 
approaches for treating PKD. 2 However, 
patient studies have demonstrated a 
remarkable heterogeneity in the onset and 
progression of the disease, suggesting that 
disease progression is infl uenced by other 
environmental and genetic factors. Recent 
studies have identifi ed the innate immune 
system as one such biological process that 
infl uences the progression of PKD. Mrug 
 et al. 3 showed that severely aff ected cpk 
mice, compared with mildly aff ected cpk 
mice, expressed higher levels of markers 
for alternatively activated macrophages, 
indicative of the innate immune response 
and eff ectors of fi brosis that are associated 
with PKD. 
 Autosomal dominant PKD (ADPKD) 
is characterized by the development of 
numerous renal cysts that slowly progress 
over the lifetime of a patient, resulting 
in end-stage renal disease later in life. 
Traditionally, the measure of glomerular 
filtration rate (GFR) has been used to 
evaluate renal function. By GFR measure-
ments, the disease is largely asymptomatic 
until the third or fourth decade. Soon 
aft er the onset of symptoms, there is a 
rapid decline in GFR, leading to end-
stage renal disease. Recently, a number of 
imaging studies, including the multi-insti-
tutional CRISP (Consortium for Radio-
logic Imaging Studies of Polycystic Kidney 
Disease) study, have provided a mecha-
nism to accurately quantify cystic disease 
progression. 4,5 These studies make it 
increasingly clear that GFR is actually a 
poor predictor of PKD progression. While 
the loss of nephrons in PKD occurs in a 
linear progression, renal function does 
not decline linearly. Rather, renal func-
tion, as measured by GFR, is maintained 
at a fairly normal level, until it reaches a 
threshold at which the small number of 
remaining nephrons can no longer main-
tain a normal function. Aft er reaching 
this threshold, the GFR declines precipi-
tously, leading to end-stage renal disease. 
For the patient, this is viewed as a sudden 
acceleration of the disease, when in 
reality the disease has been progressing all 
along. Moreover, by the time the GFR 
declines, ADPKD has progressed to such 
an extent that the only treatment is trans-
plantation. Any hope, therefore, for the 
treatment of PKD must come long before 
the disease shows symptoms. Since cysts 
are now known to begin during early 
development, perhaps even  in utero , it 
is imperative to be able to measure cyst 
progression long before symptoms 
appear. 4 Th e onset of symptoms means 
that the disease has progressed to the 
point that little normal renal parenchyma 
is left . Any treatments at this stage will 
likely be ineff ective. 
 In a follow-up to Mrug  et al. , 3 Zhou 
 et al. 6 (this issue) validated that a well-
known marker of alternatively activated 
macrophages, CD14, is highly upregulated 
in the kidneys of severely affected cpk 
mice. CD14 is a pattern recognition recep-
tor that facilitates the binding of lipopoly-
saccharides (LPSs) to the Toll-like receptors 
(TLRs) to activate the innate immune sys-
tem. CD14 is expressed at high levels on 
the cell surface of monocytes and macro-
phages, where it is membrane bound by 
glycosyl phosphatidylinositol linkage, and 
